WEE1 kinase inhibitor AZD1775 has preclinical efficacy in lkb1-deficient non-small cell lung cancer
Cancer Research Aug 19, 2017
Richer AL, et al. – This study's aspiration was to analyze the preclinical effects of AZD1775 in the context of KRAS/LKB1 in nonÂsmall cell lung cancer (NSCLC). Results reported that lack of phosphorylation of LKB1 by ATM was involved in AZD1775–mediated cytotoxicity. A clinical application was offered for AZD1775 with DNA–damaging agents in KRAS/LKB1 NSCLC.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
